Julius Rajcani
Research Subjects
Julius Rajcani has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Susan Szathmary
B Galenbio Ltd , Mosonmagyaróvár , Hungary
3 shared publicationsI. Režuchová
Slovak Academy of Sciences
2 shared publicationsKalman Szenthe
2 shared publicationsM. Kúdelová
Slovak Academy of Sciences
2 shared publicationsV. Ďurmanová
Institute of Virology, Slovak Academy of Sciences, 845 05, Bratislava, Slovakia
2 shared publicationsAgnes Tóth
1 shared publication
Latest Publications
- 1 January 2020
- Published by AEPress, s.r.o. in Acta Virologica
- Vol. 64 (2) , 264-267
Coronaviruses
The members of coronavirus family are facultative pathogens of birds and mammals, including men. From their first isolation 60 years ago, they caused smaller or larger epidemics mainly originating from China. The most recent pandemic quickly spreading worldwide has affected over 2,000,000 people.
- 1 January 2020
- Published by AEPress, s.r.o. in Acta Virologica
- Vol. 64 (2) , 264-267
Coronaviruses
The members of coronavirus family are facultative pathogens of birds and mammals, including men. From their first isolation 60 years ago, they caused smaller or larger epidemics mainly originating from China. The most recent pandemic quickly spreading worldwide has affected over 2,000,000 people.
- Open Access
- 29 June 2018
- Published by Bentham Science Publishers Ltd. in The Open Infectious Diseases Journal
- Vol. 10 (1) , 47-62
Peptide Vaccines: New Trends for Avoiding the Autoimmune Response
Background: Several marketed antiviral vaccines (such as that against hepatitis virus A and/or B, influenza virus, human papillomavirus, yellow fever virus, measles, rubella and mumps viruses) may elicit various autoimmune reactions. Results: The cause of autoimmune response due to vaccination may be: 1. the adjuvant which is regularly added to the vaccine (especially in the case of various oil substrates), 2. the specific viral component itself (a protein or glycoprotein potentially possessing cross-reactive epitopes) and/or 3. contamination of the vaccine with traces of non-viral proteins mostly cellular in origin. Believing that peptide vaccines might represent an optimal solution for avoiding the above-mentioned problems, we discuss the principles of rational design of a typical peptide vaccine which should contain oligopeptides coming either from the selected structural virion components (i.e. capsid proteins and/or envelop glycoproteins or both) or from the virus-coded non-structural polypeptides. The latter should be equally immunogenic as the structural virus proteins. Describing the feasibility of identification and design of immunogenic epitopes, our paper also deals with possible problems of peptide vaccine manufacturing. The presented data are in part based on the experience of our own, in part, they are coming from the results published by others. Conclusion: Any peptide vaccine should be able to elicit relevant and specific antibody formation, as well as an efficient cell-mediated immune response. Consequently, the properly designed peptide vaccine is expected to consist of carefully selected viral peptides, which should stimulate the receptors of helper T/CD4 cells as well as of cytotoxic (T/CD8) lymphocytes.
- 29 June 2018
- Published by Bentham Science Publishers Ltd. in The Open Infectious Diseases Journal
- Vol. 10 (1) , 47-62
Open AccessPeptide Vaccines: New Trends for Avoiding the Autoimmune Response
Background: Several marketed antiviral vaccines (such as that against hepatitis virus A and/or B, influenza virus, human papillomavirus, yellow fever virus, measles, rubella and mumps viruses) may elicit various autoimmune reactions. Results: The cause of autoimmune response due to vaccination may be: 1. the adjuvant which is regularly added to the vaccine (especially in the case of various oil substrates), 2. the specific viral component itself (a protein or glycoprotein potentially possessing cross-reactive epitopes) and/or 3. contamination of the vaccine with traces of non-viral proteins mostly cellular in origin. Believing that peptide vaccines might represent an optimal solution for avoiding the above-mentioned problems, we discuss the principles of rational design of a typical peptide vaccine which should contain oligopeptides coming either from the selected structural virion components (i.e. capsid proteins and/or envelop glycoproteins or both) or from the virus-coded non-structural polypeptides. The latter should be equally immunogenic as the structural virus proteins. Describing the feasibility of identification and design of immunogenic epitopes, our paper also deals with possible problems of peptide vaccine manufacturing. The presented data are in part based on the experience of our own, in part, they are coming from the results published by others. Conclusion: Any peptide vaccine should be able to elicit relevant and specific antibody formation, as well as an efficient cell-mediated immune response. Consequently, the properly designed peptide vaccine is expected to consist of carefully selected viral peptides, which should stimulate the receptors of helper T/CD4 cells as well as of cytotoxic (T/CD8) lymphocytes.
- 9 February 2018
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 17 (3) , 239-248
The potential of currently unavailable herpes virus vaccines
Introduction: Despite overwhelming experimental work, there are no licensed vaccines against the most frequent Alphaherpesviruses, namely herpes simplex virus 1 and 2 (HSV1 and 2) nor against the Epstein-Barr virus (EBV), a member of the subfamily Gammaherpesvirus.Areas covered: Since the DNAs of both HSVs reside in the regional sensory ganglia in a latent state (i.e. as circularized episomal molecules), a corresponding vaccine might be useful for immunotherapy rather than for prevention of primary infection. Here we describe the design of a purified subunit vaccine as well as the preparation and efficacy of a recombinant fusion protein consisting of the gD ectodomain from our domestic attenuated HSV1 strain HSZP. The EBV vaccines considered so far, were destined for prevention of infectious mononucleosis (IM) or to prevent formation of EBV related tumors. To design the EBV peptide vaccine, at least 15 carefully selected immunogenic epitopes coming from 12 virus coded proteins were bound to synthetic micro-particle carriers along with a non-specific pathogen recognizing receptor (PRR) stimulating both the T as well as B lymphocytes.Expert commentary: The efficacy of a novel EBV peptide in the rabbit model was based on criteria such as antibody formation (EA-D detected by ELISA, early and capsid proteins tested by immunoblot), presence of LMP1 antigen and of viral DNA in peripheral white blood cells. Out of 19 peptide combinations used for vaccination, at least 6 showed a satisfactory protective effect.
- 9 February 2018
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 17 (3) , 239-248
The potential of currently unavailable herpes virus vaccines
Introduction: Despite overwhelming experimental work, there are no licensed vaccines against the most frequent Alphaherpesviruses, namely herpes simplex virus 1 and 2 (HSV1 and 2) nor against the Epstein-Barr virus (EBV), a member of the subfamily Gammaherpesvirus.Areas covered: Since the DNAs of both HSVs reside in the regional sensory ganglia in a latent state (i.e. as circularized episomal molecules), a corresponding vaccine might be useful for immunotherapy rather than for prevention of primary infection. Here we describe the design of a purified subunit vaccine as well as the preparation and efficacy of a recombinant fusion protein consisting of the gD ectodomain from our domestic attenuated HSV1 strain HSZP. The EBV vaccines considered so far, were destined for prevention of infectious mononucleosis (IM) or to prevent formation of EBV related tumors. To design the EBV peptide vaccine, at least 15 carefully selected immunogenic epitopes coming from 12 virus coded proteins were bound to synthetic micro-particle carriers along with a non-specific pathogen recognizing receptor (PRR) stimulating both the T as well as B lymphocytes.Expert commentary: The efficacy of a novel EBV peptide in the rabbit model was based on criteria such as antibody formation (EA-D detected by ELISA, early and capsid proteins tested by immunoblot), presence of LMP1 antigen and of viral DNA in peripheral white blood cells. Out of 19 peptide combinations used for vaccination, at least 6 showed a satisfactory protective effect.
- Open Access
- 7 September 2016
- Published by IntechOpen
Herpes Simplex Virus 1 and 2 Vaccine Design: What can we Learn from the Past?
Herpes Simplex Virus 1 and 2 Vaccine Design: What can we Learn from the Past? | InTechOpen, Published on: 2016-09-07. Authors: Vladimíra Ďurmanová, Marian Adamkov and Július Rajčáni
- 7 September 2016
- Published by IntechOpen
Open AccessHerpes Simplex Virus 1 and 2 Vaccine Design: What can we Learn from the Past?
Herpes Simplex Virus 1 and 2 Vaccine Design: What can we Learn from the Past? | InTechOpen, Published on: 2016-09-07. Authors: Vladimíra Ďurmanová, Marian Adamkov and Július Rajčáni
- 16 September 2014
- Published by Bentham Science Publishers Ltd. in Recent Patents on Anti-Infective Drug Discovery
- Vol. 9 (1) , 62-76
Survey of Epstein Barr virus (EBV) immunogenic proteins and their epitopes: implications for vaccine preparation.
Abstract: The Epstein-Barr virus (Human herpesvirus 4) encodes approximately 80 proteins, from which 15 possess at least 90 antigenic epitopes. Many of them stimulate the T cell receptors (TCR), but a few interact with the B cell receptors (BCR). Activation of B-cells and subsequent antibody production has not only been related to at least 3 envelope glycoproteins (mostly gp350) but also to latency associated membrane proteins (LMPs). The majority of EBV epitopes (over 80) inducing either cytotoxic and/or helper T lymphocytes were located on non-structural and/or latency associated polypeptides. The former interaction mediated by CD8plus/T cells is restricted by the HLA I molecules, predominantly of HLA-A subclass. In acute infectious mononucleosis (IM) patients (about 40 %) a considerable proportion of HLA B8 restricted CTL reactivity is directed against a single peptide (RAKFKQLL) of transactivator protein BZLF1/Zta. The EBV vaccines designed so far fall into two categories: those preventing any kind of infection (including prophylaxis of EBVassociated malignancies) and those designed for therapeutic purposes (to be used in subjects already infected). Preventive vaccines protecting against acute disease (such as IM) contain, as a rule, the gp350 polypeptide(s) encoded by the BLLF1 gene. Vaccines destined for tumor prevention rather consist of peptides derived from latency associated nuclear proteins (EBNA 2, 3 and 6) and/or from oncogenic latent membrane proteins (LMP1/LMP2a). Whereas the former generates antibodies preventing virus entry, the latter would potentiate the cell mediated response. In addition to recently described and purified individual recombinant immunogenic EBV polypeptides and/or their mixes, new perspectives were opened by construction of random overlapping strongly immunogenic scrambled polypeptide(s). Further novel approaches are based on carefully selected antigenic peptides (oligopeptides) coming from both, structural as well as non-structural or latencyassociated proteins bound to suitable carriers. Any constructs based on latency-associated proteins might be useful either for immunoprophylactic therapy following bone marrow and/or heart transplantations or for the prevention of EBVrelated tumors such as lymphomas and nasopharyngeal carcinoma. Due to the growing importance of the selected immunogenic epitopes as future vaccine components, at least the half of them has been patented not only as the natural amino acid sequence but also in different variations.
- 16 September 2014
- Published by Bentham Science Publishers Ltd. in Recent Patents on Anti-Infective Drug Discovery
- Vol. 9 (1) , 62-76
Survey of Epstein Barr virus (EBV) immunogenic proteins and their epitopes: implications for vaccine preparation.
Abstract: The Epstein-Barr virus (Human herpesvirus 4) encodes approximately 80 proteins, from which 15 possess at least 90 antigenic epitopes. Many of them stimulate the T cell receptors (TCR), but a few interact with the B cell receptors (BCR). Activation of B-cells and subsequent antibody production has not only been related to at least 3 envelope glycoproteins (mostly gp350) but also to latency associated membrane proteins (LMPs). The majority of EBV epitopes (over 80) inducing either cytotoxic and/or helper T lymphocytes were located on non-structural and/or latency associated polypeptides. The former interaction mediated by CD8plus/T cells is restricted by the HLA I molecules, predominantly of HLA-A subclass. In acute infectious mononucleosis (IM) patients (about 40 %) a considerable proportion of HLA B8 restricted CTL reactivity is directed against a single peptide (RAKFKQLL) of transactivator protein BZLF1/Zta. The EBV vaccines designed so far fall into two categories: those preventing any kind of infection (including prophylaxis of EBVassociated malignancies) and those designed for therapeutic purposes (to be used in subjects already infected). Preventive vaccines protecting against acute disease (such as IM) contain, as a rule, the gp350 polypeptide(s) encoded by the BLLF1 gene. Vaccines destined for tumor prevention rather consist of peptides derived from latency associated nuclear proteins (EBNA 2, 3 and 6) and/or from oncogenic latent membrane proteins (LMP1/LMP2a). Whereas the former generates antibodies preventing virus entry, the latter would potentiate the cell mediated response. In addition to recently described and purified individual recombinant immunogenic EBV polypeptides and/or their mixes, new perspectives were opened by construction of random overlapping strongly immunogenic scrambled polypeptide(s). Further novel approaches are based on carefully selected antigenic peptides (oligopeptides) coming from both, structural as well as non-structural or latencyassociated proteins bound to suitable carriers. Any constructs based on latency-associated proteins might be useful either for immunoprophylactic therapy following bone marrow and/or heart transplantations or for the prevention of EBVrelated tumors such as lymphomas and nasopharyngeal carcinoma. Due to the growing importance of the selected immunogenic epitopes as future vaccine components, at least the half of them has been patented not only as the natural amino acid sequence but also in different variations.
- Open Access
- 28 June 2014
- Published by S. Karger AG in Intervirology
- Vol. 57 (5) , 254-269
Epstein-Barr Virus (HHV-4) Inoculation to Rabbits by Intranasal and Oral Routes Results in Subacute and/or Persistent Infection Dissimilar to Human Disease
Objective: We report the infection of New Zealand white rabbits with Epstein-Barr virus (EBV). Methods: EBV prepared in B95-8 (producer) cells was inoculated to rabbits by combined intranasal and oral routes. Blood and white blood cell (WBC) samples were taken before infection, then on days 8, 28 and 98 post-infection (p.i.). Results: Administration of either 3 × 108 (group A, 11 rabbits) or 1 × 109 (group B, 10 rabbits) EBV DNA copies per animal induced subacute and/or persistent infection. The IgG antibodies in plasma were detected by ELISA as well as by immunoblot (IB). The IB bands showed mainly antibodies to the BZRF1/Zta transactivation polypeptide (69.2%), the p54 early protein (53.4%) and to the p23 capsid protein (35.8%). No anti-EBNA1 antibody was detected throughout. Viral DNA could be detected by PCR in WBCs and/or spleen of 7 out of 21 infected rabbits (30%), while 60-80% of them showed serologic response. The transiently present EBV DNA was accompanied by LMP1 antigen. Conclusions: Rabbits developed persistent EBV infection in the absence of EBNA1 antibodies and by the lack of typical infectious mononucleosis-like syndrome. The absence of EBNA1 antibody may reflect the lack of EBNA1 in B cells of EBV-inoculated rabbits.
- 28 June 2014
- Published by S. Karger AG in Intervirology
- Vol. 57 (5) , 254-269
Open AccessEpstein-Barr Virus (HHV-4) Inoculation to Rabbits by Intranasal and Oral Routes Results in Subacute and/or Persistent Infection Dissimilar to Human Disease
Objective: We report the infection of New Zealand white rabbits with Epstein-Barr virus (EBV). Methods: EBV prepared in B95-8 (producer) cells was inoculated to rabbits by combined intranasal and oral routes. Blood and white blood cell (WBC) samples were taken before infection, then on days 8, 28 and 98 post-infection (p.i.). Results: Administration of either 3 × 108 (group A, 11 rabbits) or 1 × 109 (group B, 10 rabbits) EBV DNA copies per animal induced subacute and/or persistent infection. The IgG antibodies in plasma were detected by ELISA as well as by immunoblot (IB). The IB bands showed mainly antibodies to the BZRF1/Zta transactivation polypeptide (69.2%), the p54 early protein (53.4%) and to the p23 capsid protein (35.8%). No anti-EBNA1 antibody was detected throughout. Viral DNA could be detected by PCR in WBCs and/or spleen of 7 out of 21 infected rabbits (30%), while 60-80% of them showed serologic response. The transiently present EBV DNA was accompanied by LMP1 antigen. Conclusions: Rabbits developed persistent EBV infection in the absence of EBNA1 antibodies and by the lack of typical infectious mononucleosis-like syndrome. The absence of EBNA1 antibody may reflect the lack of EBNA1 in B cells of EBV-inoculated rabbits.
- Open Access
- 20 August 2010
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 5 (5) , 554-571
Diagnostic role of p16/INK4A protein in Human Papillomavirus (HPV) induced cervical dysplasia
The p16/INK4A protein is a cellular regulatory polypeptide over-expressed in the presence of high levels of the Human Papillomavirus (HPV) coded E7 protein. This review outlines the use of p16 antigen staining in cervical biopsies as well as in PAP smears summarizing the corresponding literature and commenting the authors’ own experience. The p16 antigen is a reliable marker for dysplastic cells in CINII/CINIII (HSIL) lesions as viewed in cervical biopsies. When PAP smears were examined at large scale screening for p16 antigenreactive and atypical cells, considerable variations could be found especially in ASCUS graded lesions. Therefore, the presence of p16-reactive atypical cells in PAP smears should be interpreted together with the cytological signs of dysplasia, such as the altered N/C ratio. In addition, women revealing p16-positive ASCUS/LSIL specimens should be examined for the presence of HPV DNA. Detection of HPV DNA alone, i.e. in the absence of cytological screening has a low predictive value, since the clearance of HPV may occur even in the absence of morphological alterations. Combined cytological as well as molecular follow up contributes to the efficiency of diagnostic and increases the probability of correct interpretation of the pre-cancerous lesions by non-invasive techniques.
- 20 August 2010
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 5 (5) , 554-571
Open AccessDiagnostic role of p16/INK4A protein in Human Papillomavirus (HPV) induced cervical dysplasia
The p16/INK4A protein is a cellular regulatory polypeptide over-expressed in the presence of high levels of the Human Papillomavirus (HPV) coded E7 protein. This review outlines the use of p16 antigen staining in cervical biopsies as well as in PAP smears summarizing the corresponding literature and commenting the authors’ own experience. The p16 antigen is a reliable marker for dysplastic cells in CINII/CINIII (HSIL) lesions as viewed in cervical biopsies. When PAP smears were examined at large scale screening for p16 antigenreactive and atypical cells, considerable variations could be found especially in ASCUS graded lesions. Therefore, the presence of p16-reactive atypical cells in PAP smears should be interpreted together with the cytological signs of dysplasia, such as the altered N/C ratio. In addition, women revealing p16-positive ASCUS/LSIL specimens should be examined for the presence of HPV DNA. Detection of HPV DNA alone, i.e. in the absence of cytological screening has a low predictive value, since the clearance of HPV may occur even in the absence of morphological alterations. Combined cytological as well as molecular follow up contributes to the efficiency of diagnostic and increases the probability of correct interpretation of the pre-cancerous lesions by non-invasive techniques.
- 1 January 2008
- Published by Springer Nature in Folia Microbiologica
- Vol. 53 (1) , 73-83
Immune response and cytokine production following immunization with experimental herpes simplex virus 1 (HSV-1) vaccines
Balb/c mice were immunized with the recombinant fusion protein gD1/313 (FpgD1/313 representing the ectodomain of HSV-1 gD), with the non-pathogenic ANGpath gE-del virus, with the plasmid pcDNA3.1-gD expressing full-length gD1 and with the recombinant immediate early (IE) HSV-1 protein ICP27. Specific antibodies against these antigens (as detected by ELISA) reached high titers with the exception of the DNA vaccine. High-grade protection against challenge with the virulent strain SC16 was found following immunization with the pcDNA3.1-gD plasmid and with the gE-del virus. Medium grade, but satisfactory protection developed after immunization with the FpgD1/313 and minimum grade protection was seen upon immunization with the IE/ICP27 polypeptide. A considerable response of peripheral blood cells (PBL) and splenocytes in the lymphocyte transformation test (LTT) was found in mice immunized with FpgD1/313, with the pcDNA3.1-gD plasmid and with the live ANGpathgE-del virus. For lymphocyte stimulation in vitro, the FpgD1/313 antigen was less effective than the purified gD1/313 polypeptide (cleaved off from the fusion protein); both proteins elicited higher proliferation at the 5 μg per 0.1 mL dose than at the 1 μg per 0.1 mL dose. The secretion of Th type 1 (TNF, IFN-γ and IL-2) and Th type 2 (IL-4 and IL-6) cytokines was tested in the medium fluid of purified PBL and splenocyte cultures; their absolute values were expressed in relative indexes. The PBL from FpgD1/313 immunized mice showed increased secretion of both TH1 (TNF) as well as TH2 (IL-4) cytokines (7–10-fold, respectively). Splenocytes from FpgD1/313 immunized mice showed a significant (23-fold) increase in IL-4 production.
- 1 January 2008
- Published by Springer Nature in Folia Microbiologica
- Vol. 53 (1) , 73-83
Immune response and cytokine production following immunization with experimental herpes simplex virus 1 (HSV-1) vaccines
Balb/c mice were immunized with the recombinant fusion protein gD1/313 (FpgD1/313 representing the ectodomain of HSV-1 gD), with the non-pathogenic ANGpath gE-del virus, with the plasmid pcDNA3.1-gD expressing full-length gD1 and with the recombinant immediate early (IE) HSV-1 protein ICP27. Specific antibodies against these antigens (as detected by ELISA) reached high titers with the exception of the DNA vaccine. High-grade protection against challenge with the virulent strain SC16 was found following immunization with the pcDNA3.1-gD plasmid and with the gE-del virus. Medium grade, but satisfactory protection developed after immunization with the FpgD1/313 and minimum grade protection was seen upon immunization with the IE/ICP27 polypeptide. A considerable response of peripheral blood cells (PBL) and splenocytes in the lymphocyte transformation test (LTT) was found in mice immunized with FpgD1/313, with the pcDNA3.1-gD plasmid and with the live ANGpathgE-del virus. For lymphocyte stimulation in vitro, the FpgD1/313 antigen was less effective than the purified gD1/313 polypeptide (cleaved off from the fusion protein); both proteins elicited higher proliferation at the 5 μg per 0.1 mL dose than at the 1 μg per 0.1 mL dose. The secretion of Th type 1 (TNF, IFN-γ and IL-2) and Th type 2 (IL-4 and IL-6) cytokines was tested in the medium fluid of purified PBL and splenocyte cultures; their absolute values were expressed in relative indexes. The PBL from FpgD1/313 immunized mice showed increased secretion of both TH1 (TNF) as well as TH2 (IL-4) cytokines (7–10-fold, respectively). Splenocytes from FpgD1/313 immunized mice showed a significant (23-fold) increase in IL-4 production.
- 1 January 2007
- Vol. 51 (2) , 77-100
Reactivation of latent DNA viruses during immunosuppression: basic contemplation.
Immunosuppression (ISP) affects the outcome of acute virus primoinfection as well as the course of virus latency. ISP may result from viral infection of the immune cells. This infection can be either transient, as in measles virus infection, or progressive as in Human immunodeficiency virus (HIV-1, 2) infections, which proceed to acquired immunodeficiency syndrome (AIDS). Innate ISP occurs due to various congenital defects of cells, participating within immune response. In the majority of cases, ISP may be initiated by physical causes (e.g. irradiation) or by chemical substances including drugs used for post-transplantation therapeutic regimens. The hallmark of ISP is the impairment of B or T lymphocyte functions. Helper T lymphocytes produce a great variety of cytokines providing B lymphocyte proliferation and cytotoxic T cell maturation. The mature and/or activated memory cytotoxic T lymphocytes destroy the target cells, which synthesize virus-specific proteins. Since many ISP drugs hamper or downregulate the proliferation of B and T lymphocytes, their administration creates favorable conditions for the replication of reactivated DNA viruses otherwise produced in low amounts. Thus, ISP causes an extensive increase in the low-grade production of persisting virus, which might regularly occur during latency. In addition to reactivation of virus latency, ISP potentiates the replication and spread of any intercurrent infectious agent, whether bacterial, parasitic, yeast or fungal origin.
- 1 January 2007
- Vol. 51 (2) , 77-100
Reactivation of latent DNA viruses during immunosuppression: basic contemplation.
Immunosuppression (ISP) affects the outcome of acute virus primoinfection as well as the course of virus latency. ISP may result from viral infection of the immune cells. This infection can be either transient, as in measles virus infection, or progressive as in Human immunodeficiency virus (HIV-1, 2) infections, which proceed to acquired immunodeficiency syndrome (AIDS). Innate ISP occurs due to various congenital defects of cells, participating within immune response. In the majority of cases, ISP may be initiated by physical causes (e.g. irradiation) or by chemical substances including drugs used for post-transplantation therapeutic regimens. The hallmark of ISP is the impairment of B or T lymphocyte functions. Helper T lymphocytes produce a great variety of cytokines providing B lymphocyte proliferation and cytotoxic T cell maturation. The mature and/or activated memory cytotoxic T lymphocytes destroy the target cells, which synthesize virus-specific proteins. Since many ISP drugs hamper or downregulate the proliferation of B and T lymphocytes, their administration creates favorable conditions for the replication of reactivated DNA viruses otherwise produced in low amounts. Thus, ISP causes an extensive increase in the low-grade production of persisting virus, which might regularly occur during latency. In addition to reactivation of virus latency, ISP potentiates the replication and spread of any intercurrent infectious agent, whether bacterial, parasitic, yeast or fungal origin.
- 1 March 2006
- Published by Springer Nature in Folia Microbiologica
- Vol. 51 (2) , 67-85
Developments in herpes simplex virus vaccines: Old problems and new challenges
Vaccination has remained the best method for preventing virus spread. The herpes simplex virus (HSV) candidate vaccines tested till now were mostly purified subunit vaccines and/or recombinant envelope glycoproteins (such as gB and gD). In many experiments performed in mice, guinea pigs and rabbits, clear-cut protection against acute virus challenge was demonstrated along with the reduction of the extent of latency, when established in the immunized host. The immunotherapeutic effect of herpes vaccines seems less convincing. However, introduction of new adjuvants, which shift the cytokine production of helper T-cells toward stimulation of cytotoxic T-cells (TH1 type cytokine response), reveals a promising development. Mathematical analysis proved that overall prophylactic vaccination of seronegative women, even when eliciting 40–60 % antibody response only, would reduce the frequency of genital herpes within the vaccinated population. Even when partially effective, immunotherapeutic vaccination might represent a suitable alternative of chronic chemotherapy in recurrent labial and genital herpes.
- 1 March 2006
- Published by Springer Nature in Folia Microbiologica
- Vol. 51 (2) , 67-85
Developments in herpes simplex virus vaccines: Old problems and new challenges
Vaccination has remained the best method for preventing virus spread. The herpes simplex virus (HSV) candidate vaccines tested till now were mostly purified subunit vaccines and/or recombinant envelope glycoproteins (such as gB and gD). In many experiments performed in mice, guinea pigs and rabbits, clear-cut protection against acute virus challenge was demonstrated along with the reduction of the extent of latency, when established in the immunized host. The immunotherapeutic effect of herpes vaccines seems less convincing. However, introduction of new adjuvants, which shift the cytokine production of helper T-cells toward stimulation of cytotoxic T-cells (TH1 type cytokine response), reveals a promising development. Mathematical analysis proved that overall prophylactic vaccination of seronegative women, even when eliciting 40–60 % antibody response only, would reduce the frequency of genital herpes within the vaccinated population. Even when partially effective, immunotherapeutic vaccination might represent a suitable alternative of chronic chemotherapy in recurrent labial and genital herpes.